Related Experiment Video
Updated: Jul 15, 2026

X-Ray Crystallography to Study the Oligomeric State Transition of the Thermotoga maritima M42 Aminopeptidase TmPep1050
Published on: May 13, 2020
Crystal structure of the Streptococcus pneumoniae mevalonate kinase in complex with diphosphomevalonate
John L Andreassi1, Patrick W Bilder, Matthew W Vetting
1DuPont Crop Protection, Stine-Haskell Research Center, Newark, Delaware 19711, USA.
Abstract:
Streptococcus pneumoniae, a ubiquitous gram-positive pathogen with an alarming, steadily evolving resistance to frontline antimicrobials, poses a severe global health threat both in the community and in the clinic. The recent discovery that diphosphomevalonate (DPM), an essential intermediate in the isoprenoid biosynthetic pathway, potently and allosterically inhibits S. pneumoniae mevalonate kinase (SpMK) without affecting the human isozyme established a new target and lead compound for antimicrobial design. Here we present the crystal structure of the first S. pneumoniae mevalonate kinase, at a resolution of 2.5 A and in complex with DPM.Mg(2+) in the active-site cleft. Structural comparison of SpMK with other members of the GHMP kinase family reveals that DPM functions as a partial bisubstrate analog (mevalonate linked to the pyrophosphoryl moiety of ATP) in that it elicits a ternary-complexlike form of the enzyme, except for localized disordering in a region that would otherwise interact with the missing portion of the nucleotide. Features of the SpMK-binding pockets are discussed in the context of established mechanistic findings and inherited human diseases linked to MK deficiency.
Insights
Researchers crystallized Streptococcus pneumoniae mevalonate kinase (SpMK) bound to diphosphomevalonate (DPM). This reveals a novel target for developing new antimicrobials against drug-resistant bacteria.
Area of Science:
- Biochemistry
- Structural Biology
- Microbiology
Background:
- Streptococcus pneumoniae is a major cause of bacterial infections with increasing antimicrobial resistance.
- The isoprenoid biosynthesis pathway is essential for bacterial survival.
- Diphosphomevalonate (DPM) was identified as a potent inhibitor of S. pneumoniae mevalonate kinase (SpMK).
Purpose of the Study:
- To determine the crystal structure of S. pneumoniae mevalonate kinase (SpMK) in complex with DPM.
- To understand the mechanism of DPM inhibition.
- To provide insights for novel antimicrobial drug design.
Main Methods:
- X-ray crystallography
- Protein structure determination
- Biochemical assays
Main Results:
- The crystal structure of SpMK complexed with DPM.Mg(2+) was determined at 2.5 A resolution.
- DPM binds to the active-site cleft of SpMK, acting as a partial bisubstrate analog.
- Structural comparisons revealed unique features of SpMK compared to other GHMP kinases.
Conclusions:
- The SpMK-DPM structure provides a blueprint for designing targeted antimicrobials.
- Inhibition of SpMK represents a promising strategy against drug-resistant S. pneumoniae.
- Understanding SpMK structure-function relationships may inform studies of related human diseases.
Related Concept Videos
ATP Synthase: Structure
ATP Synthase: Mechanism
Determination of Crystal Structures
Gene Families
Occasionally these regions can be adapted to take on new roles within the organism, becoming novel genes...
Peptidoglycan Synthesis
The Supercomplexes in the Crista Membrane

